Correspondence 0001213900-24-058938 from NKGen Biotech, Inc. (NKGN, NKGNW) (CIK 0001845459)

NKGen Biotech, Inc. (NKGN, NKGNW) (CIK 0001845459)
Date: July 3, 2024 · CIK: 0001845459 · Accession: 0001213900-24-058938

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-275094

Date

July 3, 2024

Author

Not clearly detected

Form

CORRESP

Company

NKGen Biotech, Inc. (NKGN, NKGNW) (CIK 0001845459)

Letter

VIA EDGAR Division of Corporation Finance Office of Life Sciences Re: NKGen Biotech, Inc. Registration Statement on Form S-1, as amended Filed October 19, 2023 File No. 333-275094

Dear Mr. Howes and Mr. Drory:

NKGen Biotech, Inc., a Delaware corporation (the “Company”), respectfully requests pursuant to Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on Form S-1, as amended (File No. 333-275094), be accelerated and that it be declared effective on Monday July 8, 2024 at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.

Please direct any questions regarding this filing to Michael J. Blankenship of Winston & Strawn LLP at (713) 651-2678.

Very truly yours,
NKGEN BIOTECH, INC.

Show Raw Text

CORRESP
1
filename1.htm

July 3, 2024

VIA EDGAR

Tyler Howes

Jason Drory

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    NKGen Biotech, Inc.

    Registration Statement on Form S-1, as amended

Filed October 19, 2023

File
No. 333-275094

Dear Mr. Howes and Mr. Drory:

NKGen Biotech, Inc., a Delaware
corporation (the “Company”), respectfully requests pursuant to Rule 461 under the Securities Act of 1933, as amended, that
the effective date of the Company’s Registration Statement on Form S-1, as amended (File No. 333-275094), be accelerated and that
it be declared effective on Monday July 8, 2024 at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.

Please direct any questions
regarding this filing to Michael J. Blankenship of Winston & Strawn LLP at (713) 651-2678.

    Very truly yours,

    NKGEN BIOTECH, INC.

    By:
    /s/ Paul Song

    Name:

    Paul Song

    Title:

    Chief Executive Officer

    cc:
    Michael J. Blankenship

    Winston & Strawn LLP

SecProbe.io